BBNX Beta Bionics Inc.

Price (delayed)

$13.98

Market cap

$622.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.5

Enterprise value

$599.58M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 29

We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes ...

Highlights
Beta Bionics's EPS has soared by 80% YoY and by 17% from the previous quarter
The company's gross profit has surged by 67% YoY and by 13% QoQ
BBNX's quick ratio is down by 36% year-on-year but it is up by 22% since the previous quarter
The equity has contracted by 14% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of BBNX

BBNX stock price

How has the Beta Bionics stock price performed over time
Intraday
12.29%
1 week
15.54%
1 month
36.79%
1 year
-28.12%
YTD
-54.12%
QTD
39.52%

Financial performance

How have Beta Bionics's revenue and profit performed over time
Revenue
$110.24M
Gross profit
$63M
Operating income
-$77.31M
Net income
-$66.44M
Gross margin
57.2%
Net margin
-60.3%
The company's gross profit has surged by 67% YoY and by 13% QoQ
The revenue has soared by 58% YoY and by 10% from the previous quarter
The operating income has declined by 42% year-on-year and by 8% since the previous quarter
The net margin is up by 41% YoY and by 17% from the previous quarter

Price vs fundamentals

How does BBNX's price correlate with its fundamentals

Growth

What is Beta Bionics's growth rate over time

Valuation

What is Beta Bionics stock price valuation
P/E
N/A
P/B
2.29
P/S
5.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.44
Beta Bionics's EPS has soared by 80% YoY and by 17% from the previous quarter
The P/B is 27% lower than the last 4 quarters average of 2.8
The equity has contracted by 14% YoY and by 6% from the previous quarter
The revenue has soared by 58% YoY and by 10% from the previous quarter
The price to sales (P/S) is 42% less than the last 4 quarters average of 8.6

Efficiency

How efficient is Beta Bionics business performance
Beta Bionics's ROS has increased by 41% YoY and by 17% from the previous quarter
BBNX's ROA is up by 7% QoQ
The ROIC has grown by 7% from the previous quarter
The return on equity rose by 6% since the previous quarter

Dividends

What is BBNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBNX.

Financial health

How did Beta Bionics financials performed over time
The total liabilities is up by 37% year-on-year but it is down by 19% since the previous quarter
BBNX's quick ratio is down by 36% year-on-year but it is up by 22% since the previous quarter
The debt is 97% less than the equity
Beta Bionics's debt to equity has surged by 50% YoY
The equity has contracted by 14% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.